BCMA-CD3 Bispecific
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (NCT05228470) | Pfizer | 2021-12-21 |
Track BCMA-CD3 Bispecific automatically
Every clearance here is in the API, with alerts when new ones post.